Research programme: small molecule therapeutics - Accutar Biotechnology
Latest Information Update: 06 Oct 2021
At a glance
- Originator Accutar Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Lung cancer; Solid tumours
Most Recent Events
- 28 Sep 2021 Early research in Lung cancer in USA (Unspecified) before September 2021 (Accutar Biotechnology pipeline, September 2021)
- 28 Sep 2021 Early research in Solid tumours in USA (Unspecified) before September 2021 (Accutar Biotechnology pipeline, September 2021)